AquaBounty Technologies (NASDAQ:AQB – Get Free Report) and Compugen (NASDAQ:CGEN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.
Volatility and Risk
AquaBounty Technologies has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500.
Earnings and Valuation
This table compares AquaBounty Technologies and Compugen”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AquaBounty Technologies | N/A | N/A | -$18.49 million | ($1.19) | -0.76 |
| Compugen | $72.76 million | 3.05 | $35.34 million | $0.37 | 6.35 |
Compugen has higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares AquaBounty Technologies and Compugen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AquaBounty Technologies | N/A | -54.51% | -16.67% |
| Compugen | 47.97% | 47.72% | 27.51% |
Analyst Recommendations
This is a breakdown of recent recommendations for AquaBounty Technologies and Compugen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Compugen | 1 | 0 | 3 | 1 | 2.80 |
Compugen has a consensus price target of $5.00, indicating a potential upside of 112.77%. Given Compugen’s stronger consensus rating and higher probable upside, analysts plainly believe Compugen is more favorable than AquaBounty Technologies.
Summary
Compugen beats AquaBounty Technologies on 14 of the 14 factors compared between the two stocks.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Receive News & Ratings for AquaBounty Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AquaBounty Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
-limited-logo-1200x675.png){kind=logo}